
News
All series
All News


Dual-purpose therapeutics help patients with both conditions.

Knowing the approach to each step of ocular management can optimize patient vision.

Making the most of multifocal contact lenses in your practice.

This neural time warp is seen throughout the optometric examination.

Catch up on what happened in optometry during the week of August 28-September 1.

The investigators explained that the platform delivers energy that differentially heats the tissue by the impedance of the electromagnetic current.

Don’t forget to look at a patient’s optic nerve through a dilated pupil.

This new platform incorporates the SILK procedure, allowing surgeons to perform refractive correction on patients with myopia.

The FDA determined it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

In this part 2 of the pediatric myopia and keratoconus series, Drs Chan and Swartz dive into ortho-k and crosslinking in children.

The event brought together groups of people who might not otherwise have their paths crossed, focusing on the imbalance of supply and demand in eye care.

The organization says to stop using Dr. Berne’s and LightEyez MSM drops immediately due to bacterial contamination, fungal contamination, or both.

T1D is one of the most common chronic diseases affecting pediatric populations.

Catch up on what happened in optometry during the week of August 21-August 25.

Treatment requires a systematic, multifaceted approach to improve outcomes.

Lotilaner ophthalmic solution 0.25% (Xdemvy) was approved by the FDA in July, making it the first and only approved treatment for Demodex blepharitis.

How to tailor an eye examination and what technology to consider.

Physicians ask the right questions and take an aggressive approach to treatment.

Clinicians may have difficulty in making a diagnosis.

You may be wondering: What is all this hype about geographic atrophy (GA)? If you are, let us look at the enigma.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

Catch up on what happened in optometry during the week of August 14-August 18.

Fuensanta A. Vera-Diaz, OD, PhD, FAAO, Director of Research and Associate Professor of Optometry at the New England College of Optometry (NECO) repersented AAO at the first meeting of the Committee on Focus on Myopia.

Managing dry eye disease often is key to patient comfort.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.

Being a selfless provider will earn you trust and loyalty.

Oculis Holding AG announced, if approved, OCS-01 has the potential to become a new standard of care as the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

Evaluating images for quality, artifacts, and segmentation errors.



